Clinical Trial Update: A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients [Phase 3]

View source ↗

Summary

A Phase 3 study comparing FKB327 long-term safety, efficacy, and immunogenicity to Humira in rheumatoid arthritis patients has completed with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• FKB327 (adalimumab biosimilar)
• Humira (adalimumab)

Snippet

Sponsor: Fujifilm Kyowa Kirin Biologics Co., Ltd. | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2019-03-26